289 related articles for article (PubMed ID: 29324926)
21. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
22. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
24. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
[TBL] [Abstract][Full Text] [Related]
25. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous whole-body
Freitag MT; Kesch C; Cardinale J; Flechsig P; Floca R; Eiber M; Bonekamp D; Radtke JP; Kratochwil C; Kopka K; Hohenfellner M; Stenzinger A; Schlemmer HP; Haberkorn U; Giesel F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):340-347. PubMed ID: 29038888
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
28. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria.
Demirci E; Akyel R; Caner B; Alan-Selçuk N; Güven-Meşe Ş; Ocak M; Kabasakal L
Nucl Med Commun; 2020 Aug; 41(8):759-767. PubMed ID: 32453205
[TBL] [Abstract][Full Text] [Related]
29. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
[TBL] [Abstract][Full Text] [Related]
30. Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
Ma J; Yang Q; Ye X; Xu W; Chang Y; Chen R; Wang Y; Luo M; Lou Y; Yang X; Li D; Xu Y; He W; Cai M; Cao W; Ju G; Yin L; Wang J; Ren J; Ma Z; Zuo C; Ren S
Eur Radiol; 2024 Jun; 34(6):4017-4037. PubMed ID: 37981590
[TBL] [Abstract][Full Text] [Related]
31. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
32. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.
Petersen LJ; Zacho HD
Cancer Imaging; 2020 Jan; 20(1):10. PubMed ID: 31973751
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice.
Alongi P; Messina M; Pepe A; Arnone A; Vultaggio V; Longo C; Fiasconaro E; Mirabile A; Ricapito R; Blasi L; Arnone G; Messina C
Nucl Med Commun; 2024 Jul; 45(7):622-628. PubMed ID: 38835182
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
[TBL] [Abstract][Full Text] [Related]
35. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
[TBL] [Abstract][Full Text] [Related]
38. Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT.
Lennartz S; Täger P; Zopfs D; Iuga AI; Reimer RP; Zäske C; Große Hokamp N; Maintz D; Heidenreich A; Drzezga A; Kobe C; Persigehl T
Clin Nucl Med; 2021 Apr; 46(4):303-309. PubMed ID: 33443954
[TBL] [Abstract][Full Text] [Related]
39. A Comparative Study of
Gupta M; Choudhury PS; Hazarika D; Rawal S
World J Nucl Med; 2017; 16(3):186-191. PubMed ID: 28670175
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific membrane antigen expression in melanoma metastases.
Snow H; Hazell S; Francis N; Mohammed K; O'Neill S; Davies E; Mansfield D; Messiou C; Hujairi N; Nicol D; Harrington K; Smith M
J Cutan Pathol; 2020 Dec; 47(12):1115-1122. PubMed ID: 32529651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
